Overview

  • Product nameAnti-EPM2A antibody
    See all EPM2A primary antibodies
  • Description
    Mouse monoclonal to EPM2A
  • Tested applicationsSuitable for: WB, ELISA, Flow Cytmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
    Predicted to work with: Cow, Dog
  • Immunogen

    Recombinant tagged fragment: GNGPHHDRCC TYNENNLVDG VYCLPIGHWI EATGHTNEMK HTTDFYFNIA GHQAMHYSRI LPNIWLGSCP RQVEHVTIKL KHELGITAVM NFQTEWDIV, corresponding to amino acids 101-199 of Human EPM2A

  • Positive control
    • PC-12 cell lysate

Properties

Applications

Our Abpromise guarantee covers the use of ab76994 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 - 5 µg/ml. Predicted molecular weight: 37 kDa.
ELISA Use at an assay dependent concentration. Detection limit is approximately 3ng/ml as a capture antibody when tested against the immunogen.
Flow Cyt Use 1µg for 106 cells. ab170191-Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody.

Target

  • FunctionDual specificity protein phosphatase. May be involved in the control of glycogen metabolism, particularly in monitoring for and preventing the formation of poorly branched glycogen molecules (polyglucosans). Acts as a scaffold protein to facilitate PPP1R3C/PTG ubiquitination by NHLRC1/malin. Forms a complex with NHLRC1/malin and HSP70 and this complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system (UPS). Isoform 2, an inactive phosphatase, could function as a dominant-negative regulator for the phosphatase activity of isoform 1.
  • Tissue specificityExpressed in heart, skeletal muscle, kidney, pancreas and brain. Isoform 4 is also expressed in the placenta.
  • Involvement in diseaseDefects in EPM2A are a cause of progressive myoclonic epilepsy type 2 (EPM2) [MIM:254780]; also known as Lafora disease. EPM2 is an autosomal recessive and severe form of adolescent-onset progressive epilepsy. Typically, as seizures increase in frequency, cognitive function declines towards dementia, and affected individuals die usually within 10 years after onset. EPM2 occurs worldwide, but it is particularly common in the mediterranean countries of southern Europe and northern Africa, in southern India and in the Middle East. At the cellular level, it is characterized by accumulation of starch-like polyglucosans called Lafora bodies (LBs) that are most abundant in organs with the highest glucose metabolism: brain, heart, liver and skeletal muscle. Among other conditions involving polyglucosans, EPM2 is unique in that the inclusions are in neuronal dendrites but not axons and the forming polyglucosan fibrils are associated with the endoplasmic reticulum.
  • Sequence similaritiesBelongs to the protein-tyrosine phosphatase family.
    Contains 1 CBM20 (carbohydrate binding type-20) domain.
    Contains 1 tyrosine-protein phosphatase domain.
  • Post-translational
    modifications
    Polyubiquitinated by NHLRC1/malin.
    Phosphorylation on Ser-25 by AMPK affects the phosphatase activity of the enzyme and its ability to homodimerize and interact with NHLRC1, PPP1R3C or PRKAA2.
  • Cellular localizationCytoplasm; Cytoplasm. Nucleus; Endoplasmic reticulum. Cell membrane. Nucleus. Also found in the nucleus; Endoplasmic reticulum. Cell membrane. Primarily associated with polyribosomes at the endoplasmic reticulum, also found at the plasma membrane and Cytoplasm. Under glycogenolytic conditions localizes to the nucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • Epilepsy progressive myoclonus type 2 Lafora disease (laforin) antibody
    • Epilepsy progressive myoclonus type 2A Lafora disease (laforin) antibody
    • EPM2 antibody
    • Epm2a antibody
    • Epm2a gene antibody
    • EPM2A_HUMAN antibody
    • Lafora PTPase antibody
    • Laforin antibody
    • LAFPTPase antibody
    • LD antibody
    • LDE antibody
    • MELF antibody
    • RP3-466P17.2 antibody
    see all

Anti-EPM2A antibody images

  • Anti-EPM2A antibody (ab76994) at 5 µg/ml + immunogen at 0.2 µg/ml

    Secondary
    Goat Anti-Mouse IgG (H&L)-HRP Conjugate at 1/5000 dilution
    Developed using the ECL technique

    Predicted band size : 37 kDa
    Observed band size : 37 kDa
  • Anti-EPM2A antibody (ab76994) at 5 µg/ml + PC-12 cell lysate at 25 µg

    Secondary
    Goat Anti-Mouse IgG (H&L)-HRP Conjugate at 1/2500 dilution
    Developed using the ECL technique

    Predicted band size : 37 kDa
    Observed band size : 35 kDa (why is the actual band size different from the predicted?)
  • Overlay histogram showing HeLa cells stained with ab76994 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab76994, 1µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG2a [ICIGG2A] (ab91361, 1µg/1x106 cells) used under the same conditions. Unlabelled sample (blue line). Acquisition of >5,000 events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter.

References for Anti-EPM2A antibody (ab76994)

ab76994 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab76994.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"